Replies to post #156591 on Biotech Values

[DewDiligence]

If GILD pursues approval in both genotypes do you agree the FDA would request separate filings due to the large disparity in SVR rates?

The FDA would discourage a combined filing, IMO; if GILD persisted with such an application, the FDA might restrict the label to gentotypes-1 and -2. However, as noted in #msg-84287176, I don’t GILD will put itself in this position.